Control
Recent:Pan.
Aug 31 |
et al., Biomedicines, doi:10.3390/biomedicines13092133 | CX3CR1–TLR4 Axis as a Shared Neuroimmune Target in COVID-19 and Epilepsy: Integrative Transcriptomics and Gabapentin Repositioning |
| In silico study showing that gabapentin may be beneficial for COVID-19 treatment through shared neuroinflammatory pathways with epilepsy. Authors performed integrative transcriptomic analysis of COVID-19 peripheral blood mononuclear cells.. | ||
Jul 31 2022 |
et al., The Clinical Respiratory Journal, doi:10.1111/crj.13529 | The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐ related cough: A randomized, controlled clinical trial |
| 11% longer hospitalization (p=0.23) and 97% worse recovery (p<0.0001). RCT 180 hospitalized COVID-19 patients showing improved cough symptoms and shorter hospitalization with montelukast/gabapentin compared to gabapentin. For gabapentin vs. dextromethorphan there was no significant difference in hospitalizat.. | ||